391 related articles for article (PubMed ID: 21133894)
1. Chemokine receptor CCR5: from AIDS to atherosclerosis.
Jones KL; Maguire JJ; Davenport AP
Br J Pharmacol; 2011 Apr; 162(7):1453-69. PubMed ID: 21133894
[TBL] [Abstract][Full Text] [Related]
2. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist.
Blanpain C; Migeotte I; Lee B; Vakili J; Doranz BJ; Govaerts C; Vassart G; Doms RW; Parmentier M
Blood; 1999 Sep; 94(6):1899-905. PubMed ID: 10477718
[TBL] [Abstract][Full Text] [Related]
3. Heterozygous defect in HIV-1 coreceptor CCR5 and chemokine production.
Yang JY; Togni M; Widmer U
Cytokine; 1999 Jan; 11(1):1-7. PubMed ID: 10080873
[TBL] [Abstract][Full Text] [Related]
4. In vivo evolution of HIV-1 co-receptor usage and sensitivity to chemokine-mediated suppression.
Scarlatti G; Tresoldi E; Björndal A; Fredriksson R; Colognesi C; Deng HK; Malnati MS; Plebani A; Siccardi AG; Littman DR; Fenyö EM; Lusso P
Nat Med; 1997 Nov; 3(11):1259-65. PubMed ID: 9359702
[TBL] [Abstract][Full Text] [Related]
5. Molecular anatomy of CCR5 engagement by physiologic and viral chemokines and HIV-1 envelope glycoproteins: differences in primary structural requirements for RANTES, MIP-1 alpha, and vMIP-II Binding.
Navenot JM; Wang ZX; Trent JO; Murray JL; Hu QX; DeLeeuw L; Moore PS; Chang Y; Peiper SC
J Mol Biol; 2001 Nov; 313(5):1181-93. PubMed ID: 11700073
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of the CCR5 antagonist maraviroc in reducing early, ritonavir-induced atherogenesis and advanced plaque progression in mice.
Cipriani S; Francisci D; Mencarelli A; Renga B; Schiaroli E; D'Amore C; Baldelli F; Fiorucci S
Circulation; 2013 May; 127(21):2114-24. PubMed ID: 23633271
[TBL] [Abstract][Full Text] [Related]
7. Effect of CCR5 receptor antagonists on endocytosis of the human CCR5 receptor in CHO-K1 cells.
Longden J; Cooke EL; Hill SJ
Br J Pharmacol; 2008 Apr; 153(7):1513-27. PubMed ID: 18223665
[TBL] [Abstract][Full Text] [Related]
8. CCR5 genotype and plasma beta-chemokine concentration of Brazilian HIV-infected individuals.
Mikawa AY; Tagliavini SA; Costa PI
Braz J Med Biol Res; 2002 Nov; 35(11):1333-7. PubMed ID: 12426633
[TBL] [Abstract][Full Text] [Related]
9. The role of chemokines and their receptors in the rejection of pig islet tissue xenografts.
Solomon MF; Kuziel WA; Mann DA; Simeonovic CJ
Xenotransplantation; 2003 Mar; 10(2):164-77. PubMed ID: 12588649
[TBL] [Abstract][Full Text] [Related]
10. Blockade of CC chemokine receptor 5 (CCR5)-tropic human immunodeficiency virus-1 replication in human lymphoid tissue by CC chemokines.
Margolis LB; Glushakova S; Grivel JC; Murphy PM
J Clin Invest; 1998 May; 101(9):1876-80. PubMed ID: 9576751
[TBL] [Abstract][Full Text] [Related]
11. The LD78beta isoform of MIP-1alpha is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages.
Aquaro S; Menten P; Struyf S; Proost P; Van Damme J; De Clercq E; Schols D
J Virol; 2001 May; 75(9):4402-6. PubMed ID: 11287590
[TBL] [Abstract][Full Text] [Related]
12. Evidences of the cooperative role of the chemokines CCL3, CCL4 and CCL5 and its receptors CCR1+ and CCR5+ in RANKL+ cell migration throughout experimental periodontitis in mice.
Repeke CE; Ferreira SB; Claudino M; Silveira EM; de Assis GF; Avila-Campos MJ; Silva JS; Garlet GP
Bone; 2010 Apr; 46(4):1122-30. PubMed ID: 20053385
[TBL] [Abstract][Full Text] [Related]
13. Antigen stimulation induces HIV envelope gp120-specific CD4(+) T cells to secrete CCR5 ligands and suppress HIV infection.
Kaur G; Tuen M; Virland D; Cohen S; Mehra NK; Münz C; Abdelwahab S; Garzino-Demo A; Hioe CE
Virology; 2007 Dec; 369(1):214-25. PubMed ID: 17765942
[TBL] [Abstract][Full Text] [Related]
14. The core domain of chemokines binds CCR5 extracellular domains while their amino terminus interacts with the transmembrane helix bundle.
Blanpain C; Doranz BJ; Bondue A; Govaerts C; De Leener A; Vassart G; Doms RW; Proudfoot A; Parmentier M
J Biol Chem; 2003 Feb; 278(7):5179-87. PubMed ID: 12466283
[TBL] [Abstract][Full Text] [Related]
15. Gene polymorphisms in CCR5, CCR2, SDF1 and RANTES among Chinese Han population with HIV-1 infection.
Li H; Liu TJ; Hong ZH
Infect Genet Evol; 2014 Jun; 24():99-104. PubMed ID: 24650919
[TBL] [Abstract][Full Text] [Related]
16. gp120 induces cell death in human neuroblastoma cells through the CXCR4 and CCR5 chemokine receptors.
Catani MV; Corasaniti MT; Navarra M; Nisticò G; Finazzi-Agrò A; Melino G
J Neurochem; 2000 Jun; 74(6):2373-9. PubMed ID: 10820198
[TBL] [Abstract][Full Text] [Related]
17. Chemokine receptor 5 and its ligands in the immune response to murine tuberculosis.
Badewa AP; Quinton LJ; Shellito JE; Mason CM
Tuberculosis (Edinb); 2005 May; 85(3):185-95. PubMed ID: 15850756
[TBL] [Abstract][Full Text] [Related]
18. Regulated on activation, normal T cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis.
Marino AP; da Silva A; dos Santos P; Pinto LM; Gazzinelli RT; Teixeira MM; Lannes-Vieira J
Circulation; 2004 Sep; 110(11):1443-9. PubMed ID: 15337689
[TBL] [Abstract][Full Text] [Related]
19. Relationship between the chemokine receptor CCR5 and microglia in neurological disorders: consequences of targeting CCR5 on neuroinflammation, neuronal death and regeneration in a model of epilepsy.
Louboutin JP; Strayer DS
CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):815-29. PubMed ID: 24047524
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of HIV-1 infection by viral chemokine U83A via high-affinity CCR5 interactions that block human chemokine-induced leukocyte chemotaxis and receptor internalization.
Catusse J; Parry CM; Dewin DR; Gompels UA
Blood; 2007 May; 109(9):3633-9. PubMed ID: 17209056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
